Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001140361-25-042045·Indivior Pharmaceuticals, Inc.
Schedule 13D ownership disclosure
INDIVIOR PLC
Ordinary Shares, $0.50 nominal value per share · CUSIP: G4766E116
Event date: 2025-11-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Oaktree Value Opportunities Fund, L.P.
Shares: 5,005,808 · Class: 4%
- Oaktree London Liquid Value Opportunities Fund (VOF), L.P.
Shares: 2,108,224 · Class: 1.7%
- Oaktree Phoenix Investment Fund, L.P.
Shares: 310,503 · Class: 0.2%
- Oaktree Capital Management, L.P.
Shares: 1,320,549 · Class: 1.1%
- Oaktree Fund GP I, L.P.
Shares: 7,424,535 · Class: 5.9%
- Oaktree Capital Holdings, LLCReported CIK 0001790787
Shares: 8,745,084 · Class: 7%
- Oaktree Capital Group Holdings GP, LLC
Shares: 8,745,084 · Class: 7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-25-042045
- Form type
- SCHEDULE 13D/A
- Filer
- Indivior Pharmaceuticals, Inc.
- CIK
- CIK 1625297
- Filed
- Nov 13, 2025
- Reporting period
- Nov 10, 2025
- Description
- Schedule 13D beneficial ownership